风险提示：股市有风险，投资需谨慎。 来源：金融界 民生健康属于化学制药板块，主营业务为维生素与矿物质补充剂系列产品，该业务占公司营收比重超过 96%。公司还涉及毛发医疗、医疗美容等相关领域。2025年一季度，公司实现营业收入2.71亿元，净利 润6271万元。 公司公告显示，截至2025年7月31日，已累计回购133万股，占总股本0.37%，回购金额1726.28万元。此 次回购股份将用于实施股权激励计划，回购价格区间为11.83元至13.82元/股。 资金流向方面，8月4日主力资金净流出1045.75万元，占流通市值比为0.59%。近五个交易日主力资金累 计净流入6469.14万元，占流通市值比为3.66%。 截至2025年8月4日15时，民生健康股价报15.97元，较前一交易日下跌2.32%。当日成交量为16.47万 手，成交金额达2.62亿元。盘中最高触及16.17元，最低下探至15.62元，振幅为3.36%。 ...

（文章来源：证券日报） 证券日报网讯 8月4日晚间，民生健康发布公告称，截至2025年7月31日，公司通过回购专用证券账户以 集中竞价交易方式已累计回购股份1，328，000股，占公司当前总股本的0.37%。 ...

一、 回购股份的基本情况 证券代码：301507 证券简称：民生健康 公告编号：2025-036 杭州民生健康药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 重要内容提示： 回购方案的实施情况：截至 2025 年 7 月 31 日，杭州民生健康药业股份有 限公司（以下简称"公司"）通过回购专用证券账户，以集中竞价交易方式已累 计回购股份 1,328,000 股，占公司当前总股本的 0.37%，最高成交价为 13.82 元/ 股，最低成交价为 11.83 元/股，支付金额为 17,262,815 元（不含交易费用）。 公司于 2025 年 3 月 19 日召开第二届董事会第七次会议，审议通过《关于以 集中竞价交易方式回购公司股份的议案》，同意公司通过集中竞价交易方式以自 有资金回购部分社会公众股份，用于股权激励。回购价格不超过人民币 19.80 元 /股；预计回购股份数量为 130 万-145 万股，预计回购资金总额不超过人民币 2,871.00 万元，具体以实际回购情况为准；回购实施期限为自 ...

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 从薪酬分布看，A股原料药上市公司董秘年薪平均值为60.84万元。经统计，处于50万以下、50万-100万、100万以上各区间的人数分别为23人、19人、5人，占比分别为49%、40%、11%。 其中，年薪排行前五的董秘分别为国邦医药的龚裕达、赛分科技的王中蕾、科源制药的李春桦、奥锐特的李芳芳、浙江医药的邵旻之。其年薪分别为193.09万元、151.4万元、120万元、117 年薪不足20万的董秘共三人，分别为新天地的谢雨珊、东亚药业的周剑波、欧康医药的曹永强，三人2024年年薪分别为17.42万元、18.75万元、19.07万元。从任职年限看，三位薪酬最低董 从接待投资者次数看，各上市公司接待情况差异较大。经统计，年接待次数小于10次的公司数量为20家，占比43%；接待次数为10次-100次的公司数量为19家，占比40%；接待次数为100次-3 其中，接待投资者次数0次的公司共5家，分别为奥翔药业、川宁生物、新赣江、峆一药业、新天地。 5家年接待投资者次数最多的公司分别为黄山胶囊、河化股份、博瑞医药（维权）、威尔药业、美诺华（维 ...

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，A股共有47家上市原料药公司，董事会秘书聘任总体情况如下（部分统计 口径剔除无效数据）。 从董秘的年龄分布来看，介于30-50岁的董秘是市场的中坚力量，占比共计达到60%；50岁以上的董秘 占比为38%；小于等于30岁的董秘群体占比为2%。其中，最年轻的上市公司董秘年仅30岁，为赛分科 技的王中蕾。 年薪不足20万的董秘共三人，分别为新天地的谢雨珊、东亚药业的周剑波、欧康医药的曹永强，三人 2024年年薪分别为17.42万元、18.75万元、19.07万元。从任职年限看，三位薪酬最低董秘均为近两年任 职。 从接待投资者次数看，各上市公司接待情况差异较大。经统计，年接待次数小于10次的公司数量为20 家，占比43%；接待次数为10次-100次的公司数量为19家，占比40%；接待次数为100次-300次的公司 ...

Company Overview - Minsheng Health has a diverse business structure, including vitamin and mineral supplements, probiotics, and medical beauty products [1] - The company has established a full industrial chain in the probiotics sector, enhancing its competitive advantage [2][3] Growth in Core Products - The main product, 21 Jinweita® Multivitamin Tablets, has seen a steady increase in market share [2] - Online sales have expanded significantly through three dedicated online business units, contributing to overall revenue growth [2] Probiotics Market Strategy - The company has developed a comprehensive probiotics ecosystem, including over 6,500 strains in its proprietary "Yanhuang Strain Library" [3] - Focus on functional strains and unique technologies to differentiate products in the probiotics market [3] New Product Launches - Minoxidil solution is set to launch in August 2025, while Varenicline tablets are planned for September 2025 [4] - Different marketing strategies will be employed for each product, with a focus on consumer health education for Varenicline [4] Challenges and Solutions - The decline in foot traffic at offline pharmacies poses a challenge; however, the company has built strong relationships with pharmacies to mitigate this [5] - The new skincare brand, Jisuran, aims to convert low-frequency pharmaceutical purchases into higher-frequency skincare sales [5] Organizational Structure - Each business segment operates independently, with dedicated departments for OTC, online retail, and medical beauty [6] - The company emphasizes talent retention and management efficiency to ensure sustainable growth [6] Long-term Strategic Goals - Maintain steady growth in the core vitamin and mineral supplement business [6] - Position the probiotics segment as a second growth curve to catch up with industry leaders [6]

Core Viewpoint - The strategic placement of shares in the initial public offering (IPO) of Jiyuan Group Co., Ltd. has been approved, with a total of 5,001,000 shares to be publicly issued, representing 12.50% of the total post-issue share capital [1][3]. Group 1: Strategic Placement Overview - The initial strategic placement amount is set at 1,000,200 shares, accounting for 20.00% of the total issuance [3][5]. - The strategic placement will involve four investors, with the participation of senior management and core employees through a special asset management plan [5][9]. - The total share capital of the company post-issue will be 40,001,000 shares [3]. Group 2: Investor Participation - The strategic placement is limited to investors who meet specific criteria outlined in the Implementation Rules, ensuring compliance with legal requirements [2][16]. - The senior management and core employees' asset management plan will not exceed 500,100 shares, which is 10% of the total issuance [5][9]. - Other participating investors are allowed to commit up to 60,000,000 yuan [3][5]. Group 3: Compliance and Verification - The underwriter has verified that all participating investors have provided valid documentation and guarantees regarding their qualifications [2][15]. - The strategic placement agreement stipulates that investors will not participate in the preliminary inquiry and will commit to the final issuance price [8][16]. - The lock-up period for shares acquired through the strategic placement is set at 12 months from the date of the IPO [16][28]. Group 4: Investor Profiles - Ningbo Tongshang Hui Gong Industrial Investment Fund, a large enterprise with strategic ties to the issuer, is among the investors [4][23]. - Meinian Health Industry Holding Co., Ltd., a leading health examination company, is also participating, leveraging its extensive data for collaboration [24][28]. - Hangzhou Minsheng Health Pharmaceutical Co., Ltd. is included as well, focusing on health-related products and services [29][30].

Group 1 - The core viewpoint of the article highlights a significant surge in real estate-related sectors such as engineering consulting, urban renewal, and construction services, with multiple stocks reaching their daily limit up [1] - The China Engineering Machinery Industry Association reported that excavator sales in the first half of the year reached 65,637 units, representing a year-on-year increase of 22.9%, indicating a positive outlook for the infrastructure and real estate sectors [1] - The China Index Academy noted that the land transfer revenue in first- and second-tier cities increased by over 40% in the first half of the year, with some cities nearing their total revenue from the previous year [1] Group 2 - The National Development and Reform Commission emphasized the importance of utilizing "two heavy" and "two new" funds to increase investment in key areas of new urbanization [1] - In the building materials market, futures prices for rebar and hot-rolled coil on the Shanghai Stock Exchange have seen an upward trend, reflecting increased demand [1]

Core Insights - The article discusses recent developments in the nutrition and health industry, highlighting regulatory changes, new product approvals, and market trends that could impact investment opportunities [2][3][4][5][6]. Regulatory Developments - The State Administration for Market Regulation issued a guideline clarifying the definition of commercial advertising under the Advertising Law, addressing ongoing disputes in advertising enforcement [2]. - The National Health Commission approved D-alloheptulose and four other substances as new food raw materials, indicating a push for innovation in the nutrition sector [3]. - The market regulator released multiple responses to proposals regarding health food regulations, signaling a focus on traditional Chinese medicine formulations as a potential growth area [4]. Market Trends and Investment Opportunities - Yangtuo Technology Inc. submitted an IPO application to the Hong Kong Stock Exchange, aiming to raise funds for market expansion and supply chain optimization, reflecting growing investor interest in the nutrition and health sector [5]. - A report on 68 nutrition and health companies showed an average market value increase of 20% in the first half of the year, driven by rising consumer health awareness and demand for nutritional products [6]. Company Performance - New Hope Liuhe (002001) projected a net profit of 3.3 billion to 3.75 billion yuan for the first half of 2025, representing a year-on-year growth of 50% to 70% [12]. - Brother Technology (002562) expects a net profit of 60 million to 75 million yuan for the same period, marking an increase of 325% to 431% compared to the previous year [13]. New Product Launches - Guangji Pharmaceutical (000952) received a notice of administrative penalty for information disclosure violations, indicating regulatory scrutiny in the sector [14]. - TCM brand Tongrentang launched its first OTC glucosamine product, expanding its product line in the bone and joint health category [14].

Group 1 - The company Minsheng Health (301507) plans to participate as a strategic investor in the initial public offering (IPO) of Jiyuan Group (603262) with a subscription amount not exceeding RMB 15 million [1] - Jiyuan Group has received approval from the China Securities Regulatory Commission for its IPO registration [1] - The final subscription amount will be determined based on the final allocation results announced by Jiyuan Group and its sponsor [1] Group 2 - The company's board of directors has approved the relevant proposals and authorized the management to handle related matters [1] - This external investment falls within the decision-making authority of the board and does not require submission for shareholder meeting approval [1]